8 News & Press Releases found

Check-Cap Ltd. news

Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq`s Minimum Bid Price Requirement

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), announces that onJune 22, 2022, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that

Jun. 22, 2022

Check-Cap Announces Initiation of the U.S. Pivotal Trial

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the initiation of its U.S. pivotal trial of C-Scan® at Mayo Clinic in Roche

May. 11, 2022

Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, thefirst and onlypatient-friendly preparation-freescreening test to detect polypsbeforethey may transform into colorectal cancer (CRC), today announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for its amended Inv

Feb. 6, 2022

Check-Cap Announces Publication of Peer-Reviewed Article Highlighting Safety and Patient Satisfaction Data for its Colorectal Screening Test, C-Scan

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the publication of research titled "Colorectal cancer

Nov. 21, 2021

Check-Cap Announces Grant of Patent Covering C-Scan`s Proprietary Tracking Technology in the U.S. and Additional Major Market Territories

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the United States Patent and Trademark Office (USPTO), has issued a decision to grant a patent covering C-Sc

Nov. 1, 2021